Nephros (NEPH) Receivables (2010 - 2026)

Nephros' Receivables history runs 17 years deep, the most recent figure standing at $3.5 million for Q1 2026.

• On a quarterly basis, Receivables rose 31.53% year-over-year to $3.5 million in Q1 2026; TTM through Mar 2026 was $3.5 million, a 31.53% increase from a year earlier, with the FY2025 full-year figure at $2.4 million, up 35.54% from the prior year.
• Receivables advanced to $3.5 million in Q1 2026 per NEPH's latest filing, from $2.4 million in the prior quarter.
• Across five years, Receivables topped out at $3.5 million in Q1 2026 and bottomed at $1.3 million in Q4 2022.
• The 5-year median for Receivables is $1.8 million (2024), against an average of $1.9 million.
• Across the five-year window, Receivables fell 25.94% in 2023 and soared 76.35% in 2025, its largest moves.
• Year by year, Receivables stood at $1.3 million in 2022, then increased by 16.33% to $1.5 million in 2023, then gained by 19.05% to $1.8 million in 2024, then jumped by 35.54% to $2.4 million in 2025, then surged by 45.86% to $3.5 million in 2026.
• Per Business Quant, the three latest NEPH Receivables figures stand at $3.5 million (Q1 2026), $2.4 million (Q4 2025), and $2.7 million (Q3 2025).